MA
CORT icon

Mutual Advisors’s Corcept Therapeutics CORT Stock Holding History

Mutual Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,406
Closed -$1.26M – 1101
2024
Q2 		$1.26M Buy
+34,406
New +$942K 0.04% 412
2023
Q4 		– Sell
-34,462
Closed -$939K – 1015
2023
Q3 		$939K Buy
+34,462
New +$997K 0.04% 440
2023
Q2 		– Sell
-37,424
Closed -$811K – 1010
2023
Q1 		$811K Buy
+37,424
New +$820K 0.03% 485

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Mutual Advisors's CORT Position: Q3 2024 in Review

Mutual Advisors sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 34,406 shares — an estimated $1.26M sold.

Mutual Advisors first reported a position in CORT in Q1 2023 and held it in 3 quarters. The position peaked at $1.26M in Q2 2024. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Mutual Advisors reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Mutual Advisors sold 34,406 Corcept Therapeutics shares in Q3 2024, an estimated $1.26M.
  • Mutual Advisors first reported a position in Corcept Therapeutics in Q1 2023 and held it in 3 quarters.
  • Mutual Advisors's Corcept Therapeutics position peaked at $1.26M in Q2 2024.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Mutual Advisors's 13F filing for Q3 2024, filed 25 Oct 2024.